Breast density notifications aim to educate women about the risks of high breast density, defined as having more fibroglandular tissue than fatty tissue, as visualized on a mammogram. Prompted by activists whose own breast density had obscured breast cancers on their mammograms, 38 U.S. states and Washington, DC, have enacted legislation requiring written notification of a patient's breast density (DBN) after a mammogram and language for a federal notification is forthcoming from the U.S.A. Food and Drug Administration. Yet, these notifications were developed with limited input and without extensive testing among women in the general population, and many are written at a high literacy level, often discordant with population literacy levels.
